Shin Nippon Biomedical Laboratories, Ltd. Share Price BOERSE MUENCHEN
Equities
YB3
JP3379950003
Biotechnology & Medical Research
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
8 EUR | 0.00% | +1.27% | -25.93% |
Sales 2024 | 26.45B 168M 155M 13.24B | Sales 2025 * | 30.5B 194M 179M 15.27B | Capitalization | 55.41B 353M 325M 27.74B |
---|---|---|---|---|---|
Net income 2024 | 5.53B 35.2M 32.43M 2.77B | Net income 2025 * | 4.3B 27.37M 25.22M 2.15B | EV / Sales 2024 | 2.39 x |
Net Debt 2024 * | 19.51B 124M 114M 9.77B | Net Debt 2025 * | 22.77B 145M 134M 11.4B | EV / Sales 2025 * | 2.56 x |
P/E ratio 2024 |
11.4
x | P/E ratio 2025 * |
12.9
x | Employees | - |
Yield 2024 |
3.29% | Yield 2025 * |
3.76% | Free-Float | 48.8% |
1 week | +1.27% | ||
Current month | -10.61% | ||
1 month | -10.61% | ||
3 months | -20.79% | ||
6 months | -20.79% | ||
Current year | -25.93% |
Managers | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 31/08/81 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 30/04/02 |
Terumasa Hirai
CMP | Compliance Officer | - | 31/03/84 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ichiro Nagata
BRD | Director/Board Member | 38 | 31/03/17 |
Sales & Marketing | 64 | 31/10/02 | |
Ken Takanashi
COO | Chief Operating Officer | 60 | 30/11/02 |
Date | Price | Change |
---|---|---|
31/05/24 | 8 | 0.00% |
30/05/24 | 8 | 0.00% |
29/05/24 | 8 | 0.00% |
28/05/24 | 8 | +1.91% |
27/05/24 | 7.85 | 0.00% |
Real-time BOERSE MUENCHEN, May 31, 2024 at 01:14 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.36% | 58.06B | |
-3.86% | 40.53B | |
+36.47% | 38.99B | |
+14.13% | 26.7B | |
-12.01% | 26.56B | |
-21.62% | 18.98B | |
+0.21% | 12.17B | |
+23.02% | 12B | |
+25.96% | 11.92B |
- Stock Market
- Equities
- 2395 Stock
- YB3 Stock